<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1504">
  <stage>Registered</stage>
  <submitdate>19/03/2007</submitdate>
  <approvaldate>19/03/2007</approvaldate>
  <nctid>NCT00449397</nctid>
  <trial_identification>
    <studytitle>Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis</studytitle>
    <scientifictitle>A Naturalistic, Prospective, Single Centre, Double Blinded, Fixed Dose, Randomised, Four Week Comparison Study Investigating Efficacy, Tolerability and Safety of 200 mg Per Day Versus 400 mg Per Day Quetiapine Fumarate in 200 Drug na√Øve First Episode Psychosis Patients Aged 15 to 25 Years.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>AU-SEA-0003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Psychosis</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Psychosis and personality disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Quetiapine Fumarate

Treatment: drugs: Quetiapine Fumarate


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Medication dose, Remission and response rate, exBPRSvs4, SANS, CGI - I, CGI - S, CDSS, GAF and QoL scale</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>SWN, UKU, illicit substance use, laboratory measures, altered drop-out rates</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients experiencing their first psychotic episode

          -  Male or Female

          -  Aged 15-25</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>25</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Previous treatment with antipsychotic medication (longer than 1 week)

          -  History of a clinically significant physical illness

          -  Organic disorder presenting with psychotic symptoms</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Research Sites - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AstraZeneca</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is determine the minimal effective dose and the impact on:

        1. treatment outcomes at 4, 12 and/or 48 weeks the treatment has required to treat patients
           experiencing the first psychotic episode

        2. the final maintenance doses

        3. the use of other medications

        4. the amount of changes to other antipsychotic medication

        5. the number of hospitalization days</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00449397</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gregor Berger, MD</name>
      <address>ORYGEN Research Centre/ ORYGEN Youth Health</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>